Oseni (Alogliptin Benz/Pioglitazone) Patent Expiration, LOE Window & CMS Spending

Oseni (Alogliptin Benz/Pioglitazone) by Takeda: FDA Orange Book core substance LOE 2028-06-27 (last listed 2029-06-04), 0 AB generics, $79K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN022426 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-06-27
Last Listed Patent or Exclusivity Date2029-06-04
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$79K
2024 Medicare Part D Spend$49K
2024 Medicaid Spend$30K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.